IgG4 MET Antibody Drug Conjugate Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody drug conjugates (ADCs) face challenges with chemical and physical stability, leading to ineffective or toxic compounds, particularly in targeting MET receptors for cancer therapy, where existing antibodies and linkers often result in unstable and agonistic properties.
Innovation Solution
Development of a MET ADC using an IgG4 antibody with specific heavy and light chain complementarity determining regions (CDRs) that binds MET with high affinity, conjugated with a cytotoxic agent like MMAE, to achieve stable and targeted delivery with minimal agonist activity, utilizing novel conjugation processes and payload intermediates to enhance stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ADC structures are used with existing antibodies and linkers, then the ADC can deliver cytotoxic drugs to tumor cells, but the ADC exhibits poor chemical and physical stability leading to ineffective or toxic compounds
Solution Approach 1:
The patent applies parameter changes by modifying the antibody isotype from IgG1 or IgG2 to IgG4, which fundamentally alters the antibody's biochemical properties including reduced FcRn binding affinity and different proteolytic susceptibility. This parameter change in the antibody structure directly improves the chemical and physical stability of the ADC while reducing off-target toxicity effects
2Reliability
If existing MET antibodies are used in ADC format, then the ADC can target MET receptors, but the ADC exhibits agonistic properties that reduce therapeutic efficacy
Solution Approach 1:
The patent changes the antibody isotype parameter to IgG4, which has different conformational properties and binding characteristics compared to IgG1 or IgG2. This parameter change eliminates the agonistic activity observed with other isotypes while maintaining high-affinity MET binding, thereby improving therapeutic efficacy without the harmful agonist effects
3Productivity
If ADCs are designed with potent cytotoxic payloads, then the ADC can kill tumor cells effectively, but the ADC has significantly shorter elimination half-lives compared to parental antibodies
Solution Approach 1:
By changing the antibody isotype to IgG4, the patent modifies the pharmacokinetic parameters of the ADC. The IgG4 isotype exhibits different clearance rates and half-life characteristics compared to conventional isotypes, allowing the ADC to maintain both potent cytotoxic efficacy and improved duration of action in the circulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MET ADC exhibits increased stability, efficacy in treating MET-expressing tumors, including resistant types, with comparable internalization and degradation activity to unconjugated antibodies, and improved physical and chemical stability, demonstrating enhanced therapeutic potential for hard-to-treat cancers.
Implementation Method 1
an IgG4 antibody that binds to MET
Implementation Method 2
take advantage of the specificity of monoclonal antibodies (mAbs) to deliver potent cytotoxic drugs selectively to antigen-expressing tumor cells
Data Source
AI summary
Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.